Psychostimulants for depression

The Cochrane Database of Systematic Reviews
M CandyM King

Abstract

Depression is common, disabling, costly and under-treated. There are problems in the current first-line drug treatment, antidepressants, for moderate or severe depression. There is a body of research that has evaluated the effect of psychostimulants (PS) in the treatment of depression. This has not been reviewed systematically. To determine the effectiveness of PS in the treatment of depression and to assess adverse events associated with PS. Databases CCDANCTR-Studies and CCDANCTR-References were searched on 21/6/2006. Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PsycInfo, AMED, CINAHL, Dissertation Abstracts and the National Health Service Research Register were searched. Randomised controlled trials (RCTs) assessing the effectiveness of PS were included. The trial population comprised adults of either sex with a diagnosis of depression. Two review authors extracted the data independently and assessed trial quality. Meta-analysis was considered for trials with comparable key characteristics. The primary outcome was depression symptoms, based on a continuous outcome, using the standardised mean difference (SMD), or a dichotomous measure of clinical response, using odds ratios (OR), with 95% confidence inter...Continue Reading

References

Oct 1, 1978·The American Journal of Psychiatry·D P van Kammen, D L Murphy
Feb 1, 1979·Journal of Communication Disorders·M NataleJ Jaffe
Jan 1, 1979·International Pharmacopsychiatry·A ElizurS Davidson
Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jun 1, 1975·Journal of the American Geriatrics Society·S E Kaplitz
Aug 1, 1991·Journal of Clinical Psychopharmacology·R T JoffeA J Levitt
Dec 1, 1991·Journal of Clinical Psychopharmacology·J W JeffersonR Rosenfeld
Oct 1, 1991·Journal of Psychoactive Drugs·D M Ziedonis, T R Kosten
Jan 1, 1991·Psychosomatics·P MasandG B Murray
Oct 1, 1990·Journal of Affective Disorders·H M KravitzL Fogg
May 1, 1990·The American Journal of Psychiatry·C E CoffeyW B Saunders
Mar 1, 1989·Biological Psychiatry·K Y Little
Mar 1, 1987·Archives of General Psychiatry·R J Chiarello, J O Cole
Sep 1, 1985·Journal of Affective Disorders·M M Robertson, M R Trimble
Mar 1, 1986·Journal of Clinical Pharmacology·A J GianniniR H Loiselle
May 1, 1987·Biological Psychiatry·G J NaylorP Connelly
Apr 1, 1986·International Clinical Psychopharmacology·J Cookson, T Silverstone
Aug 1, 1987·Clinical Pharmacology and Therapeutics·H de WitC E Johanson
Jan 1, 1985·Progress in Neuro-psychopharmacology & Biological Psychiatry·T R InselD L Murphy
Nov 1, 1973·Archives of General Psychiatry·J BuckmanI Stevenson
Nov 1, 1974·Psychological Medicine·A J BondM H Lader
Nov 1, 1974·Psychological Medicine·M H LaderD C James
Jun 18, 1974·Psychopharmacologia·R M PostF K Goodwin
Jan 1, 1974·Psychopharmacologia·B R BallingerI H Stevenson
Jul 1, 1972·Clinical Pharmacology and Therapeutics·K RickelsH S Wentz
Jan 1, 1973·The Journal of Clinical Pharmacology and New Drugs·H M van Praag, J Korf
Jun 1, 1967·The British Journal of Psychiatry : the Journal of Mental Science·J W HunterJ F Scott
Jan 16, 1971·British Medical Journal·T G BlashkiB Davies
Mar 1, 1972·Archives of General Psychiatry·J Fawcett, J W Maas
Nov 1, 1965·The Australian & New Zealand Journal of Obstetrics & Gynaecology·N Davis
Sep 1, 1970·Clinical Pharmacology and Therapeutics·K RickelsP T Hesbacher
Jun 1, 1983·Archives of General Psychiatry·T R InselM Linnoila
Jul 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·T P ZahnD L Murphy
Jan 1, 1983·Psychopharmacology·T R InselD L Murphy
Aug 1, 1983·Journal of Clinical Psychopharmacology·P P Roy-ByrneR H Gerner
Jan 1, 1980·Progress in Neuro-psychopharmacology·P D Hrdina, Y D Lapierre
Jun 8, 1995·Journal of Affective Disorders·J L Claghorn, M D Lesem
Jan 1, 1995·International Journal of Psychiatry in Medicine·F FernandezP Ruiz

❮ Previous
Next ❯

Citations

Jul 21, 2010·Psychopharmacology·Joris C VersterBerend Olivier
May 31, 2013·Journal of Biomedical Research·Qigang Zhou, Mengying Liu
Oct 31, 2014·Journal of Mental Health·Rasika JayasekaraKate Deuter
Feb 4, 2014·Therapeutic Advances in Psychopharmacology·Maju Mathew KoolaJan A Fawcett
May 9, 2013·The Australian and New Zealand Journal of Psychiatry·Raymond W LamUlrich Hegerl
May 5, 2010·Annals of Internal Medicine·Tonya L Fancher, Richard L Kravitz
Oct 15, 2009·Acta Psychiatrica Scandinavica·Bradley Ng
Feb 26, 2016·Nature Neuroscience·Quentin J M HuysMichael J Frank
Mar 28, 2017·Scientific Reports·Frank M SchmidtUlrich Hegerl
Dec 18, 2013·Pharmacological Reviews·Suzanne WoodStephan G Anagnostaras
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Klaus LindeLevente Kriston
May 14, 2020·The International Journal of Neuropsychopharmacology·Rachael W TaylorAnthony J Cleare
Feb 24, 2015·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Raymond W LamAtul Khullar
Mar 5, 2016·Journal of Psychoactive Drugs·Marc VogelKenneth M Dürsteler
Jul 7, 2010·Neuroscience and Biobehavioral Reviews·Michael T Treadway, David H Zald

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.